Should I buy Thermo Fisher Scientific stock in 2025?
Is Thermo Fisher Scientific stock a buy right now?
As of early May 2025, Thermo Fisher Scientific (TMO) shares trade near $420 on the NYSE, with an average daily volume of approximately 2.3 million shares. While the stock has recently experienced downward momentum—trading below major moving averages and posting a one-year decline of 27%—recent developments signal resilience and promise. TMO reported a steady Q1 2025 with flat revenue but impressive gains in GAAP EPS (+15%) and a 10% increase to its annual dividend, underscoring ongoing operational strength. Moreover, the company continues to innovate, launching new products in precision medicine and lab automation, and has begun its strategic acquisition of Solventum’s purification business, expected to broaden its revenue base. Market sentiment appears cautiously constructive: investors recognize temporary pressures but also see potential for a turnaround amid stable cash flows, robust balance sheets, and long-term expansion in healthcare and diagnostics. In this highly defensible sector—vital for life sciences, pharmaceuticals, and emerging biotech—Thermo Fisher remains a global leader. A consensus of more than 30 major national and international banks currently sets a target price of $546, reflecting confidence in Thermo Fisher's fundamentals and its ability to weather sector volatility while capitalizing on future growth opportunities.
- Industry leader with diversified revenue across life sciences, diagnostics, and lab products.
- Consistent cash flow and a strong balance sheet support innovation and shareholder returns.
- Ongoing product launches in proteomics, lab automation, and semiconductor solutions.
- Strategic acquisitions, like Solventum’s purification unit, boost long-term growth outlook.
- 10% increase to dividend and $2 billion recent share buyback signal management confidence.
- Short-term technical signals indicate ongoing selling pressure and possible near-term volatility.
- Modest organic revenue growth (1%) may not satisfy aggressive growth-oriented investors.
- What is Thermo Fisher Scientific?
- How much is Thermo Fisher Scientific stock?
- Our full analysis on Thermo Fisher Scientific </b>stock
- How to buy Thermo Fisher Scientific stock in United States?
- Our 7 tips for buying Thermo Fisher Scientific stock
- The latest news about Thermo Fisher Scientific
- FAQ
Why trust HelloSafe?
At HelloSafe, our expert has been monitoring Thermo Fisher Scientific's performance for more than three years. Each month, over a million users in the United States rely on us to interpret market trends and highlight the best investment opportunities. Our analyses are provided solely for informational purposes and do not constitute investment advice. In line with our ethical charter, we have never been, and will never be, compensated by Thermo Fisher Scientific.
What is Thermo Fisher Scientific?
| Indicator | Value | Analysis |
|---|---|---|
| 🏳️ Nationality | United States | Based in Massachusetts; benefits from strong US life sciences ecosystem. |
| 💼 Market | NYSE: TMO | Listed on NYSE, offers high liquidity for US-based investors. |
| 🏛️ ISIN code | US8835561023 | ISIN uniquely identifies Thermo Fisher shares for global investors. |
| 👤 CEO | Marc N. Casper | CEO since 2009; recognized for steady leadership and disciplined growth. |
| 🏢 Market cap | $158.5 billion | Large-cap status reflects market leadership and broad investor interest. |
| 📈 Revenue | $10.36 billion (Q1 2025) | Revenue is stable year-over-year; signals resilient demand in key sectors. |
| 💹 EBITDA | ~$2.3 billion (Q1 2025 est.) | Strong EBITDA margin supports ongoing investment and shareholder returns. |
| 📊 P/E Ratio (Price/Earnings) | 24.6 (TTM) | Below sector highs; may indicate fair value with room for long-term growth. |
How much is Thermo Fisher Scientific stock?
The price of Thermo Fisher Scientific stock is falling this week. As of today, TMO is trading at $419.89, reflecting a 1.22% decrease in the last 24 hours and a 2.12% drop over the past week. The company’s current market capitalization stands at $158.5 billion, with an average 3-month trading volume of 2.26 million shares. The stock has a P/E ratio of 24.63 and offers a dividend yield of 0.41%, while the beta sits at 0.87, indicating modest volatility compared to the overall market.
Given recent downward trends and subdued price movement, investors may wish to monitor for signs of technical stability before making new commitments.
Check out the USA's best brokers!Compare brokersOur full analysis on Thermo Fisher Scientific stock
Having thoroughly reviewed Thermo Fisher Scientific’s latest quarterly results, as well as the stock’s three-year price performance, our integrated analysis—leveraging financial fundamentals, technical signals, and sector comparables—reveals a compelling investment landscape. Using proprietary models to aggregate multiple market and competitor datapoints, we identify a scenario where the business’s quality, resilience, and current technical set-up intersect at a potentially favorable juncture. So, why might Thermo Fisher Scientific stock once again become a strategic entry point into the elite life sciences and laboratory technology segment in 2025?
Recent Performance and Market Context
Thermo Fisher Scientific (NYSE: TMO), a global leader in scientific instrumentation, reagents, and biotechnological services, has experienced pronounced volatility over the past twelve months. The stock currently trades at $419.89 (as of May 2, 2025), marking a significant correction of approximately 27% year-over-year and 19% year-to-date, positioning it firmly in the lower decile of its 52-week price range ($409.85 – $627.88).
Yet, amidst this correction, several positive events have unfolded. The Q1 2025 earnings release highlighted a robust 15% increase in GAAP EPS and marked Thermo Fisher’s ability to withstand sector headwinds, continuing the pattern of resilient performance established in prior years. Management remains committed to returning capital to shareholders, increasing its dividend by 10% and executing $2 billion in share repurchases. This is set against the backdrop of a broader life sciences sector that, despite short-term cyclical softness, exhibits enduring demand tailwinds: aging populations, expanding healthcare access, growing biopharma R&D spend, and the rapid proliferation of precision medicine.
Throughout the past three years, Thermo Fisher has not only preserved its market dominance but also actively diversified through accretive acquisitions and a broadening portfolio. Its recent agreement to acquire Solventum’s Purification & Filtration unit for $4.1 billion signals continued commitment to scale and innovation—an essential competitive edge in an increasingly consolidating sector.
Technical Analysis
From a technical stand-point, Thermo Fisher’s profile currently displays all the hallmarks of a well-supported long-term opportunity in the making:
- Relative Strength Index (RSI 14): At 38.6, TMO approaches oversold territory, a zone that often precedes bullish reversals in high-quality blue chips.
- MACD: Bearish at -18.57, yet with momentum waning, suggesting the correction could be nearing exhaustion.
- Moving Averages: The stock trades below its 20-day, 50-day, 100-day, and 200-day averages, underscoring a protracted downtrend but also flagging that the downside may be increasingly limited as valuation normalizes.
- Support & Resistance: The price is clustering close to strong support levels at $414 and $409, with immediate resistance at $425 and $432. This compression can often precede shifts in market sentiment, especially when underlying fundamentals remain robust.
- ADX (14) at 40+: Indicates trend strength but, paired with high negative momentum, may signal an environment conducive to bottom formation.
Combined, these technical signals frame TMO within a context where technical risk is declining while the probability of medium-term recovery rises—a setup often attractive for entry by disciplined investors seeking inflection points.
Fundamental Analysis
Thermo Fisher’s fundamentals remain remarkably resilient:
- Revenue and Profitability: Q1 2025 saw revenues stabilize at $10.36 billion, up 1% organically, and a 15% GAAP EPS increase despite broader economic softness. Operating margins remain healthy (GAAP 16.6%, Adjusted 21.9%), a testament to operational excellence and pricing power.
- Valuation: The correction has reset TMO’s valuation: trailing P/E is 24.6 (forward P/E at 18.7), with a PEG ratio of 1.61—favorable relative to peers given TMO’s secular growth profile and industry leadership. Price/Sales at 3.74 and Price/Book at 3.21 further indicate a normalization toward historical averages and relative value in the sector.
- Business Strengths:
- Market Leadership: The largest, most diversified “picks and shovels” provider to biotech, pharma, and diagnostics industries.
- Innovation Pipeline: Major product launches in automated laboratory systems and proteomics (e.g., Vulcan Automated Lab, Olink Reveal), as well as sustainability leadership via energy-saving lab equipment.
- Execution Track Record: Management consistency, rigorous capital allocation, and agile PPI Business System drive adaptivity and margin defense.
- Strategic Expansion: Ongoing vertical integration (including the proposed Solventum deal) enhances market share and operating leverage, reinforcing Thermo Fisher’s defensible moat in a rapidly evolving scientific solutions market.
Volume and Liquidity
- Average Daily Volume: At 2.26 million shares, trading conditions consistently allow for sizable institutional flows without material price disruption, ensuring robust market depth and tight spreads.
- Share Float & Buybacks: The float remains actively managed through sizable repurchases, supporting per-share value accretion and dynamic market valuation. The $2 billion repurchase in Q1 2025 exemplifies a shareholder-aligned approach and unwavering management confidence.
This liquidity profile meets or exceeds the standards institutional investors expect for portfolio construction and trade execution efficiency, providing additional assurance during volatile market periods.
Catalysts and Positive Outlook
Thermo Fisher is poised for a potential resurgence, underpinned by tangible catalysts:
- Integration of Solventum Purification & Filtration Unit: This transformative acquisition enhances Thermo Fisher’s offering in high-margin consumables, expanding revenue streams and synergy opportunities already targeted by management.
- Next-Generation Product Launches: Innovations in semiconductor analysis and precision medicine (e.g., Olink Reveal, Vulcan Automated Lab) extend Thermo Fisher’s relevance and pricing leverage in secular growth areas.
- ESG and Sustainability Focus: Increasing adoption of energy-efficient laboratory equipment aligns with institutional ESG mandates and regulatory momentum—likely to drive incremental market share gains.
- Partnerships and Platform Expansion: The strategic collaboration with the Chan Zuckerberg Institute and expansion of real-world data registries positions TMO at the forefront of translational research and clinical effectiveness analytics.
- Sector Tailwinds: Secular shifts—including increases in chronic disease prevalence, global pharmaceutical innovation, and government incentives for biomanufacturing—continue to buoy demand for Thermo Fisher’s broad suite of solutions.
In combination, these factors not only reinforce the company’s market position but also set the stage for above-trend growth as cyclical pressures abate.
Investment Strategies
Taking into account the confluence of technical and fundamental factors, several strategic perspectives merit consideration:
- Short-Term Opportunities:
- The oversold RSI, multi-month price compression near support, and approaching catalyst events (guidance update, Solventum integration) present a potential mean reversion setup. Tactical investors may consider staged entries around technical support.
- Medium-Term Horizons:
- Anticipated reacceleration in biotech and medical R&D, plus visible cost and revenue synergies, suggest TMO could outperform as operational benefits are realized. Movement above initial resistance levels ($425–$437) could confirm a trend reversal, with the potential for swift recovery toward historical averages.
- Long-Term Positioning:
- With the current valuation reset, Thermo Fisher offers a unique blend of growth, stability, and innovation leadership difficult to match among sector peers. For investors with multi-year outlooks, current price levels represent a historically advantageous basis to capitalize on the company’s compounding capabilities, market share gains, and commitment to returning value via dividends and repurchases.
Is It the Right Time to Buy Thermo Fisher Scientific?
While no investment is without risk, the present constellation of factors makes Thermo Fisher Scientific an exceedingly compelling candidate for renewed attention. The stock’s significant pullback has recalibrated valuation metrics to attractive levels rarely seen for a global category leader whose fundamentals remain robust and improving. Technical indicators, while highlighting past weakness, now suggest the potential for a reversal as the stock approaches historically reliable support zones.
Perhaps most importantly, the alignment of new product launches, strategic acquisitions, and secular market tailwinds with Thermo Fisher’s proven execution promise to re-ignite top-line momentum and margin expansion as the year unfolds. For thoughtful investors seeking exposure to the long-term growth engines of healthcare innovation, biomanufacturing, and scientific research, TMO’s current set-up seems to represent an excellent opportunity—particularly for those with the patience to look beyond near-term technical noise.
In summary, Thermo Fisher Scientific combines formidable sector positioning, prudent financial management, and a powerful innovation pipeline—elements that justify renewed interest and careful consideration of this stock as it potentially enters a new bullish phase. With catalysts on the horizon and robust operational foundations, TMO offers a blend of resilience and upside that may soon be recognized in a rerating of its share price. Investors willing to take a position at these technically attractive levels may find their conviction rewarded as market sentiment turns more constructive.
How to buy Thermo Fisher Scientific stock in United States?
Buying Thermo Fisher Scientific (TMO) stock online is both straightforward and secure when you use a regulated U.S. broker. Retail investors can choose from two main approaches: direct (spot) purchase of shares for long-term holding, or trading Contracts for Difference (CFDs), which allow speculation on price movements with leverage. Both methods are accessible through widely-trusted brokerage platforms. As with any investment, it’s important to consider your goals and risk tolerance before proceeding. For a detailed comparison of leading brokers and their fees for buying TMO stock, please refer to our broker comparison further down the page.
Spot Buying
A spot (or “cash”) purchase of Thermo Fisher Scientific stock means you directly buy shares on the New York Stock Exchange and become an official shareholder, entitled to dividends and voting rights. Most U.S. brokers charge a transparent per-order commission, typically between $0 and $10, depending on the platform.
Important Information
For example: If the Thermo Fisher Scientific share price is $419.89, you can purchase about 2 full shares with a $1,000 investment, considering an average brokerage fee of $5.
Gain Scenario: If the stock price rises by 10%, your shares would be worth $1,100.
Result: That’s a $100 gross gain, or +10% on your original investment (before taxes or miscellaneous fees).
Trading via CFD
CFDs (Contracts for Difference) offer a flexible way to gain exposure to Thermo Fisher Scientific’s share price without owning the underlying stock. Instead, you speculate on price changes and can use leverage—magnifying both potential gains and losses. CFD providers charge a spread (the gap between buying and selling prices) and overnight financing fees if you hold positions beyond a trading day.
Important Information
Suppose you open a CFD position on TMO with $1,000 and apply 5x leverage: your market exposure is $5,000.
Gain Scenario: If TMO’s stock rises 8%, your position gains 8% × 5 = 40%.
Result: You’d make a $400 gain on your $1,000 margin (excluding fees and financing costs).
Final Advice
Before investing in Thermo Fisher Scientific, be sure to compare different brokers’ fees, order execution quality, available trading tools, and regulatory protections. The right choice depends on your investment objectives—whether you prefer the stability of owning shares outright, or the flexibility and leverage offered by CFDs. To make your decision easier, our comprehensive broker comparator with updated fees and features is available further down the page.
Is eToro reliable?
Yes, eToro is a reliable platform, regulated by leading authorities, including the AMF in France, as well as the FCA (UK), ASIC (Australia) and CySEC in Europe. With over 30 million users worldwide, eToro is widely recognized for its security and transparency. Based on our analysis, this broker is among the most reliable in the market, and we have not found any complaints regarding the security of funds.
Why choose eToro?
With eToro, you don’t need to be an expert to get started. Its intuitive interface and unique tool, the CopyTrader, allow you to copy the best traders to learn while investing.
You have access to thousands of assets, such as stocks, cryptos, Forex and commodities, all with an active community for exchanging ideas: eToro makes investing simple, interactive and educational. It's a bit like the Spotify of investing.
What are the fees at eToro?
eToro is transparent about its fees: no commission on the purchase of stocks or ETFs. Spreads vary depending on the asset, but remain very affordable.
Deposits are free, and withdrawals are set at $5. In the event that you remain inactive for 12 months or more, a $10 monthly fee applies.
Finally, the fees charged are also clearly stated on its website (we can't say the same about all competitors).
Who is eToro for?
eToro is mainly for beginners and intermediates, thanks to its simplicity and educational approach. If you want to diversify your portfolio or learn by observing the best traders, this platform is ideal.
Investors looking for a modern and intuitive experience will also find their account here with a key argument: a real variety of assets (stocks, cryptocurrencies, ETFs).
Is it easy to withdraw your money from eToro?
Yes, withdrawing your winnings from eToro is as easy as investing. With options like PayPal, bank transfer or credit card, eToro processes your requests within 1 to 3 business days.
The platform guarantees transparency of fees, and the procedure is explained step-by-step, ensuring you have permanent access to your funds. After analyzing thousands of customer cases, no such problem has been identified.
Is eToro reliable?
Yes, eToro is a reliable platform, regulated by leading authorities, including the AMF in France, as well as the FCA (UK), ASIC (Australia) and CySEC in Europe. With over 30 million users worldwide, eToro is widely recognized for its security and transparency. Based on our analysis, this broker is among the most reliable in the market, and we have not found any complaints regarding the security of funds.
Why choose eToro?
With eToro, you don’t need to be an expert to get started. Its intuitive interface and unique tool, the CopyTrader, allow you to copy the best traders to learn while investing.
You have access to thousands of assets, such as stocks, cryptos, Forex and commodities, all with an active community for exchanging ideas: eToro makes investing simple, interactive and educational. It's a bit like the Spotify of investing.
What are the fees at eToro?
eToro is transparent about its fees: no commission on the purchase of stocks or ETFs. Spreads vary depending on the asset, but remain very affordable.
Deposits are free, and withdrawals are set at $5. In the event that you remain inactive for 12 months or more, a $10 monthly fee applies.
Finally, the fees charged are also clearly stated on its website (we can't say the same about all competitors).
Who is eToro for?
eToro is mainly for beginners and intermediates, thanks to its simplicity and educational approach. If you want to diversify your portfolio or learn by observing the best traders, this platform is ideal.
Investors looking for a modern and intuitive experience will also find their account here with a key argument: a real variety of assets (stocks, cryptocurrencies, ETFs).
Is it easy to withdraw your money from eToro?
Yes, withdrawing your winnings from eToro is as easy as investing. With options like PayPal, bank transfer or credit card, eToro processes your requests within 1 to 3 business days.
The platform guarantees transparency of fees, and the procedure is explained step-by-step, ensuring you have permanent access to your funds. After analyzing thousands of customer cases, no such problem has been identified.
Is IG reliable?
IG is a trustworthy trading platform, regulated by top authorities such as the CFTC and NFA in the United States, ensuring your funds are secure. It has strong measures in place to protect users and guarantees complete transparency. Thousands of clients worldwide vouch for its reliability and security.
Why choose IG?
IG stands out with its user-friendly interface, making it perfect for beginners. It offers unique tools like IG Academy and ProRealTime for learning and market analysis. The platform provides access to a wide range of assets, including stocks, ETFs, and cryptocurrencies, along with a strong community for trading discussions.
What are the fees at IG?
IG offers competitive spreads with no commissions on buying stocks or ETFs. Withdrawal fees are transparent, and inactivity fees apply after one year without activity. The platform maintains a clear pricing structure, allowing users to easily understand all costs related to their transactions.
Who is IG for?
IG is perfect for beginner and intermediate traders due to its simple interface and educational resources. It also caters to experienced investors with advanced trading tools. Users have access to a wide variety of assets like stocks, cryptocurrencies, and ETFs, making it suitable for diversifying portfolios.
Is it easy to withdraw money from IG?
Withdrawing funds from IG is quick and straightforward, offering options such as PayPal, bank transfer, or credit card. Processing times are usually 1 to 3 business days. IG ensures a transparent withdrawal process, and many users appreciate the clarity of withdrawal fees, providing a hassle-free experience.
Is IG reliable?
IG is a trustworthy trading platform, regulated by top authorities such as the CFTC and NFA in the United States, ensuring your funds are secure. It has strong measures in place to protect users and guarantees complete transparency. Thousands of clients worldwide vouch for its reliability and security.
Why choose IG?
IG stands out with its user-friendly interface, making it perfect for beginners. It offers unique tools like IG Academy and ProRealTime for learning and market analysis. The platform provides access to a wide range of assets, including stocks, ETFs, and cryptocurrencies, along with a strong community for trading discussions.
What are the fees at IG?
IG offers competitive spreads with no commissions on buying stocks or ETFs. Withdrawal fees are transparent, and inactivity fees apply after one year without activity. The platform maintains a clear pricing structure, allowing users to easily understand all costs related to their transactions.
Who is IG for?
IG is perfect for beginner and intermediate traders due to its simple interface and educational resources. It also caters to experienced investors with advanced trading tools. Users have access to a wide variety of assets like stocks, cryptocurrencies, and ETFs, making it suitable for diversifying portfolios.
Is it easy to withdraw money from IG?
Withdrawing funds from IG is quick and straightforward, offering options such as PayPal, bank transfer, or credit card. Processing times are usually 1 to 3 business days. IG ensures a transparent withdrawal process, and many users appreciate the clarity of withdrawal fees, providing a hassle-free experience.
Is AvaTrade reliable?
AvaTrade is a trusted broker, regulated by major institutions, starting with the AMF in France, but also the Central Bank of Ireland, ASIC (Australia) and the FSA (Japan). Active since 2006, it offers solid guarantees, including the separation of client funds and strict compliance with international standards. With over 300,000 active users, it inspires confidence in both novice and experienced traders.
Why choose AvaTrade?
AvaTrade combines simplicity and expertise. Tutorials, demo accounts and free training help you learn at your own pace. Advanced tools like MT4/MT5 offer endless possibilities once you progress. You don't need to be an expert: AvaTrade adapts to you.
What are the fees at AvaTrade?
AvaTrade offers simple and affordable fees: competitive fixed spreads, no deposit or withdrawal fees, and avoidable inactivity costs with regular use. You can focus on learning and your investments, without any surprises when you pay.
Who is AvaTrade for?
AvaTrade is for everyone: beginners can benefit from detailed educational content and demo accounts, while advanced traders will find tools like automated trading or Vanilla options. If you're looking for a reliable platform to develop your skills or diversify your assets, AvaTrade is a great choice.
Is it easy to withdraw money from AvaTrade?
Yes, AvaTrade offers a fast and secure withdrawal process. Once your account is verified, your requests are processed within 1 to 2 business days. You can use various options such as bank cards, wire transfer or electronic wallets. Everything is designed to offer you fast, clear and secure access.
Is AvaTrade reliable?
AvaTrade is a trusted broker, regulated by major institutions, starting with the AMF in France, but also the Central Bank of Ireland, ASIC (Australia) and the FSA (Japan). Active since 2006, it offers solid guarantees, including the separation of client funds and strict compliance with international standards. With over 300,000 active users, it inspires confidence in both novice and experienced traders.
Why choose AvaTrade?
AvaTrade combines simplicity and expertise. Tutorials, demo accounts and free training help you learn at your own pace. Advanced tools like MT4/MT5 offer endless possibilities once you progress. You don't need to be an expert: AvaTrade adapts to you.
What are the fees at AvaTrade?
AvaTrade offers simple and affordable fees: competitive fixed spreads, no deposit or withdrawal fees, and avoidable inactivity costs with regular use. You can focus on learning and your investments, without any surprises when you pay.
Who is AvaTrade for?
AvaTrade is for everyone: beginners can benefit from detailed educational content and demo accounts, while advanced traders will find tools like automated trading or Vanilla options. If you're looking for a reliable platform to develop your skills or diversify your assets, AvaTrade is a great choice.
Is it easy to withdraw money from AvaTrade?
Yes, AvaTrade offers a fast and secure withdrawal process. Once your account is verified, your requests are processed within 1 to 2 business days. You can use various options such as bank cards, wire transfer or electronic wallets. Everything is designed to offer you fast, clear and secure access.
Our 7 tips for buying Thermo Fisher Scientific stock
| 📊 Step | 📝 Specific tip for Thermo Fisher Scientific |
|---|---|
| Analyze the market | Review trends in healthcare and diagnostics, paying special attention to Thermo Fisher Scientific’s position as a market leader and its exposure to high-growth life science sectors. |
| Choose the right trading platform | Use a reputable U.S. brokerage that provides access to the NYSE, strong research tools, and low commissions to facilitate efficient buying of TMO stock. |
| Define your investment budget | Consider allocating only a portion of your portfolio to Thermo Fisher Scientific, factoring in its recent price volatility and diversifying alongside other healthcare or science stocks. |
| Choose a strategy (short or long term) | Favor a long-term investing approach, as Thermo Fisher Scientific’s innovation pipeline and recent acquisitions may drive value growth over several years, despite short-term price weakness. |
| Monitor news and financial results | Regularly follow quarterly earnings, new product launches, and acquisition updates, as these can influence Thermo Fisher Scientific’s stock price and provide potential buy or add-on opportunities. |
| Use risk management tools | Set stop-loss orders or trailing stops to help protect your investment from further downside in case of continued market pressure on Thermo Fisher Scientific shares. |
| Sell at the right time | Consider harvesting gains or trimming your position when TMO stock approaches technical resistance levels or before major earnings announcements that could introduce heightened volatility. |
The latest news about Thermo Fisher Scientific
On April 23, 2025, Thermo Fisher Scientific released Q1 results showing a 15% year-over-year increase in GAAP EPS. The company reported Q1 2025 GAAP earnings per share of $3.98, representing a significant 15% growth versus the same period last year, while adjusted EPS reached $5.15, up 1% year-over-year. Revenue for the quarter came in at $10.36 billion, remaining flat overall but reflecting 1% organic growth. Despite macroeconomic pressures, margin performance remained robust, with the GAAP operating margin improving to 16.6%. These results underscore the company’s operational resilience amid industry headwinds, supporting analyst confidence in Thermo Fisher’s core earnings power.
Thermo Fisher Scientific increased its dividend by 10% for Q1 2025, reinforcing shareholder return commitment. The quarterly dividend, paid in April 2025, was raised to $0.43 per share, up 10% from the previous rate—a move made possible by sustained strong free cash flow and a low dividend payout ratio. This progressive dividend policy, coupled with an ongoing $2 billion share repurchase in Q1, demonstrates management’s firm long-term commitment to returning value to shareholders and underlines the company’s healthy balance sheet. For U.S. investors, this combination of dividend growth and buybacks is a positive signal of sustainable capital allocation discipline.
Thermo Fisher announced the $4.1 billion acquisition of Solventum's Purification & Filtration business in April 2025. This strategic acquisition, expected to close later in the year, will notably enhance Thermo Fisher’s presence in the fast-growing bioprocessing and pharma production market segments in North America. The move is aligned with the company’s expansion strategy and is anticipated to drive both top-line growth and operational synergies. Given Thermo Fisher’s strong track record integrating acquisitions, this bolt-on deal is viewed favorably by industry experts and is poised to strengthen its competitive position in the U.S. life sciences sector.
The launch of innovative products in Q1, including the Thermo Scientific Vulcan Automated Lab and Olink Reveal, boosts growth prospects. Product introductions targeting high-demand domains like semiconductor analysis and proteomics in the U.S. reflect Thermo Fisher’s ongoing commitment to innovation and responsiveness to evolving scientific needs. Notable releases such as the Vulcan Automated Lab for semiconductor labs and Olink Reveal kits for precision medicine are expected to enhance customer engagement across research and healthcare markets. Such launches contribute to the company’s leadership standing and bolster future revenue streams, a key growth pillar for U.S.-based operations.
Thermo Fisher’s U.S. market engagement remains robust through strategic partnerships and expanded clinical registries. The company’s collaboration with organizations like the Chan Zuckerberg Initiative and its ongoing expansion of clinical registries are strengthening its U.S. market ecosystem, facilitating broader access to data for treatment effectiveness studies. This ecosystem approach elevates Thermo Fisher’s profile as a trusted partner in the American scientific community, reinforcing its strategic foothold and providing new growth avenues in a competitive environment.
FAQ
What is the latest dividend for Thermo Fisher Scientific stock?
Thermo Fisher Scientific currently pays an annual dividend of $1.72 per share. The most recent dividend was paid on April 15, 2025, with an ex-dividend date of March 14, 2025. The company recently increased its dividend by 10%, reflecting confidence in its cash flow and a commitment to returning value to shareholders. Thermo Fisher Scientific maintains a low payout ratio, which supports the sustainability of its dividend even during industry cycles.
What is the forecast for Thermo Fisher Scientific stock in 2025, 2026, and 2027?
Based on the current share price of $419.89, the projected values are $545.86 for the end of 2025, $629.84 for the end of 2026, and $839.78 for the end of 2027. These optimistic forecasts reflect Thermo Fisher Scientific's solid foundation in life sciences, a sector known for strong structural growth and innovation. Analysts remain positive on the company’s strategy, supported by its leadership position, diversified revenues, and ongoing investments in new technologies.
Should I sell my Thermo Fisher Scientific shares?
Holding Thermo Fisher Scientific shares may be a suitable approach for long-term investors, given the company’s resilient business model, strong balance sheet, and leading position in the healthcare and diagnostics sector. Despite recent price declines, the company’s track record of operational excellence, consistent innovation, and shareholder returns through dividends and buybacks highlights its mid- to long-term growth prospects. Investors focused on fundamentals may find patience rewarding as the stock recovers alongside sector momentum.
How are Thermo Fisher Scientific shares taxed for U.S. investors?
For most U.S. investors, dividends from Thermo Fisher Scientific are subject to federal income tax, typically at qualified dividend rates if held in a taxable account. Shares can be held within tax-advantaged accounts like IRAs or 401(k)s, deferring tax or offering tax-free growth, depending on the account type. Capital gains tax applies when selling shares for a profit, with favorable long-term rates if held over one year. There’s no U.S. withholding tax for domestic investors, but always consult your tax advisor for details specific to your situation.
What is the latest dividend for Thermo Fisher Scientific stock?
Thermo Fisher Scientific currently pays an annual dividend of $1.72 per share. The most recent dividend was paid on April 15, 2025, with an ex-dividend date of March 14, 2025. The company recently increased its dividend by 10%, reflecting confidence in its cash flow and a commitment to returning value to shareholders. Thermo Fisher Scientific maintains a low payout ratio, which supports the sustainability of its dividend even during industry cycles.
What is the forecast for Thermo Fisher Scientific stock in 2025, 2026, and 2027?
Based on the current share price of $419.89, the projected values are $545.86 for the end of 2025, $629.84 for the end of 2026, and $839.78 for the end of 2027. These optimistic forecasts reflect Thermo Fisher Scientific's solid foundation in life sciences, a sector known for strong structural growth and innovation. Analysts remain positive on the company’s strategy, supported by its leadership position, diversified revenues, and ongoing investments in new technologies.
Should I sell my Thermo Fisher Scientific shares?
Holding Thermo Fisher Scientific shares may be a suitable approach for long-term investors, given the company’s resilient business model, strong balance sheet, and leading position in the healthcare and diagnostics sector. Despite recent price declines, the company’s track record of operational excellence, consistent innovation, and shareholder returns through dividends and buybacks highlights its mid- to long-term growth prospects. Investors focused on fundamentals may find patience rewarding as the stock recovers alongside sector momentum.
How are Thermo Fisher Scientific shares taxed for U.S. investors?
For most U.S. investors, dividends from Thermo Fisher Scientific are subject to federal income tax, typically at qualified dividend rates if held in a taxable account. Shares can be held within tax-advantaged accounts like IRAs or 401(k)s, deferring tax or offering tax-free growth, depending on the account type. Capital gains tax applies when selling shares for a profit, with favorable long-term rates if held over one year. There’s no U.S. withholding tax for domestic investors, but always consult your tax advisor for details specific to your situation.
